White Paper: Bio Data Points

By Eric Langer, president and managing partner, BioPlan Associates, Inc.

Nearly all biopharmaceutical developers use outsourcing services of some kind, whether for manufacture of clinical or commercial supplies, assays, process development, or many other activities. Outsourcing and offshoring are becoming part of mainstream operations strategy. Yet our recently released 2011 Eighth Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production indicates there has been virtually no headway made into improving relationships between clients and customers. This relationship is showing up as a substantial roadblock. As clients demand higher-level outsourced activities and increasingly greater value from their partners' services, senior managers on both sides of the fence will need to figure out a solution.

Used with permission from Life Science Leader magazine.